These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10420032)

  • 1. Tissue prostate-specific antigen and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy.
    Ogreid P; Berner A; Dahl O; Rettedal E; Fosså SD
    Eur Urol; 1999 Aug; 36(2):116-22. PubMed ID: 10420032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer.
    Parker CC; Norman AR; Huddart RA; Horwich A; Dearnaley DP
    Br J Cancer; 2002 Mar; 86(5):686-91. PubMed ID: 11875726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.
    Cho E; Mostaghel EA; Russell KJ; Liao JJ; Konodi MA; Kurland BF; Marck BT; Matsumoto AM; Dalkin BL; Montgomery RB
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):236-43. PubMed ID: 25772183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
    Kass-Iliyya A; Jovic G; Murphy C; Fisher C; Syndikus I; Jose C; Scrase CD; Graham JD; Nicol D; Sydes MR; Dearnaley D
    Eur Urol; 2018 Jun; 73(6):968-976. PubMed ID: 29307509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.
    Buskirk SJ; Pisansky TM; Atkinson EJ; Schild SE; O'Brien PC; Wolfe JT; Zincke H
    Mayo Clin Proc; 2001 Jul; 76(7):702-6. PubMed ID: 11444402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study.
    Majumder K; Nilsson S; Johansson H; Ullén A; Lennernäs B; Bergenmar M; Brandberg Y
    Eur J Cancer; 2016 Sep; 65():43-51. PubMed ID: 27459586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.
    D'Amico AV; Chen MH; de Castro M; Loffredo M; Lamb DS; Steigler A; Kantoff PW; Denham JW
    Lancet Oncol; 2012 Feb; 13(2):189-95. PubMed ID: 22112793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas.
    Szabó J; Bartók K; Krenács T; Szepesváry Z; Szende B
    Anticancer Res; 2009 Feb; 29(2):681-4. PubMed ID: 19331222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
    Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR; Presti JC; Gill H; Brooks J; Hancock SL
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopsy results after real-time ultrasound-guided transperineal implants for stage T1-T2 prostate cancer.
    Stone NN; Stock RG; Unger P; Kao J
    J Endourol; 2000 May; 14(4):375-80. PubMed ID: 10910155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.
    Katz MS; Zelefsky MJ; Venkatraman ES; Fuks Z; Hummer A; Leibel SA
    J Clin Oncol; 2003 Feb; 21(3):483-9. PubMed ID: 12560439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results.
    Cohen JK; Miller RJ; Rooker GM; Shuman BA
    Urology; 1996 Mar; 47(3):395-401. PubMed ID: 8633408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
    Buyyounouski MK; Hanlon AL; Horwitz EM; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1291-8. PubMed ID: 15817330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.